Pular para o conteúdo principal
Ranking Invest

FULC - Fulcrum Therapeutics, Inc.

Segmento: HealthcareFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Análise Ranking Invest

Valor de Mercado
$ 278.03 Mi
IVR
0.20Índice proprietário de comparação relativa: 0,20.
IVR2
-0.93Leitura proprietária complementar: -93%.
MLL
-0.93Leitura proprietária complementar: -93%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 310.70 Mi

Dívida Líquida

-$ 48.47 Mi

L4T

-$ 81.96 Mi

Indicadores Básicos

ROE

-26.38%

Índices de Previsibilidade

Receita Líquida

G0.70

Lucro

A0.12

Margem

D0.80

Índices de Tendência

Receita Líquida

F-10.40

Lucro

B7.19

Margem

A8.10

Índices de Endividamento

DIV/PAT

-0.16

DIV/L4T

0.59

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.